Clinical Trial: A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies

Study Status: RECRUITING
Recruit Status: RECRUITING
Study Type: INTERVENTIONAL

Official Title: A Phase 1, Multicenter, Open-label Study to Evaluate the Pharmacokinetics of CC-486 (Onureg�) in Subjects With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Adult Subj

Brief Summary: The purpose of this study is to evaluate the effect of moderate or severe liver impairment on the drug levels of oral azacitidine and the safety and tolerability of oral azacitidine in participants with myeloid malignancies.

Detailed Summary:
Sponsor: Bristol-Myers Squibb

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Bristol-Myers Squibb

Dates:
Date Received: January 13, 2022
Date Started: November 30, 2023
Date Completion: November 30, 2023
Last Updated: November 21, 2023
Last Verified: November 01, 2023